Reckitt Benckiser Group (LON:RKT) Trading Up 1.9% – Still a Buy?

Reckitt Benckiser Group plc (LON:RKT)’s share price rose 1.9% during trading on Monday . The stock traded as high as GBX 5,172 ($64.35) and last traded at GBX 5,166 ($64.28). Approximately 90,327,430 shares changed hands during mid-day trading, an increase of 757% from the average daily volume of 10,544,096 shares. The stock had previously closed at GBX 5,072 ($63.11).

Wall Street Analyst Weigh In

Separately, Berenberg Bank lowered their price target on Reckitt Benckiser Group from GBX 5,200 ($64.70) to GBX 5,177 ($64.41) and set a “hold” rating on the stock in a report on Wednesday, October 23rd.

Reckitt Benckiser Group Stock Up 1.9 %

The company has a quick ratio of 0.46, a current ratio of 0.69 and a debt-to-equity ratio of 112.52. The firm has a market capitalization of £35.71 billion, a PE ratio of 2,380.65, a price-to-earnings-growth ratio of 1.10 and a beta of 0.09. The business’s 50-day moving average price is GBX 4,864.56 and its 200-day moving average price is GBX 4,638.58.

Insider Buying and Selling at Reckitt Benckiser Group

In related news, insider Shannon Eisenhardt sold 1,368 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of GBX 4,723 ($58.77), for a total value of £64,610.64 ($80,391.49). Company insiders own 0.05% of the company’s stock.

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.